Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy

Cancer Journal

Volumn 8, Issue 1, 2002, Pages 79-80

  Merrick, Gregory S ^a,b   Butler, Wayne M ^a   Galbreath, Robert W ^a,c   Lief, Jonathan H ^a,c   Adamovich, Edward ^d  

^a WHEELING HOSPITAL   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c WHEELING JESUIT UNIVERSITY   (United States)

^d WHEELING HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PALLADIUM 103;

BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; LETTER; PERINEURIUM; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RADIATION DOSE; SEMINAL VESICLE; TREATMENT OUTCOME; TREATMENT PLANNING; MALE; NOTE; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR;

BRACHYTHERAPY; HUMANS; MALE; NEOPLASM INVASIVENESS; PROGNOSIS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0036359308     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200201000-00014     Document Type: Letter

References (9)

1. Merrick GS, Butler WM, Galbreath RW et al. Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy. Cancer J 2001;7:404-412.
2. D'Amico AV. Perineural invasion as a predictor of PSA outcome following local therapy for patients with clinically localized prostate cancer. Cancer J 2001;7:375-376.
3. D'Amico AV, Wu Y, Chen MH et al. Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer. J Urol 2000;165:126-130.
4. Butler WM, Merrick GS, Wallner KE et al. Extracapsular radiation dose distribution following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2001;51[suppl]:393.
5. Davis BJ, Pisansky TM, Wilson TM et al. The radial distance of extraprostatic extension of prostate carcinoma. Cancer 1999;85:2630-2637.
6. Galbreath RW, Merrick GS, Butler WM et al. Sexual function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2001;51[suppl]:99.
7. Potters L, Cha C, Oshinsky C et al. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Cancer J Sci Am 1999;5:301-306.
8. Blasko JC, Grimm PD, Sylvester JE et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000;46:839-850.
9. Merrick GS, Butler WM, Lief JH et al. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys 2001;51:40-47.